10Oct
07Oct
Candidly Launches AI-Powered Financial Guidance Platform
NEW YORK--(BUSINESS WIRE)--Candidly today announced the launch of the Candidly Intelligence Center, an enterprise-grade deterministic AI system that delivers tailored financial insights extensible across multiple financial domains. The Candidly Intelligence Center is a sophisticated multi-agentic backend system that orchestrates specialized AI agents across distinct financial domains that span both the liabilities and assets side of the balance sheet. When combined with a user-facing interface — like Cait, Candidly's conversational AI tool —...
06Oct
Quthero’s Clinical Trial Results Published in Prestigious Medical Journal
TORONTO, ONTARIO, CANADA, September 29, 2025 /EINPresswire.com/ -- Quthero, a pioneering biotech company advancing regenerative medicine through its proprietary Q-peptide platform technology, announced today that the results of their recent clinical trial have been published in the September 2025 issue of the peer-reviewed Journal of Drugs in Dermatology. Quthero's breakthrough technology enables complete regeneration of a patient's natural tissue with minimal scarring. Read More>>
01Oct
Archer Roose Wines and JetBlue Take Happy Hour to New Heights with the “Skyhigh Spritz”
NEW YORK, Oct. 1, 2025 /PRNewswire/ -- Move over, mini bottles. Archer Roose Wines and JetBlue are taking happy hour to new heights with the launch of their first signature cocktail: the Skyhigh Spritz. The new sparkling drink, crafted with Archer Roose Wines' Bubbly and a splash of cranberry juice, is designed to be mixed right from your seat. Just pop, pour, and voilà: you're your own in-flight bartender. Read More>>
26Sep
Elizabeth Banks Brings Beauty, Brains And Humor To Fine Wine
As of 2021, she is also an entrepreneur in the Spirits industry, becoming a co-owner and Chief Creative Officer of the canned, fine wine company Archer Roose Wines. She admits that you might very well find her sipping one of the company’s blends from her glam chair as she is styled with hair and makeup before a red carpet event. “By the time of the red carpet, it’s already a celebration,” she explains. “I just got ready for the Emmy’s...
26Sep
Archer Roose Wines Now Available to Pop and Pour on Princess Cruises
NEW YORK, Sept. 25, 2025 /PRNewswire/ -- Archer Roose Wines, the fast-growing canned wine brand, is now available fleetwide on Princess Cruises as its first official canned wine partner. Shipboard guests will enjoy perfect pours of Archer Roose Wines' Bubbly, Pinot Noir, Rosé and Sauvignon Blanc varietals on all voyages starting this September – whether poolside, on excursions, in casinos, via Princess' Ocean Now® and in-room delivery, at Princess Cay or at its Alaska lodges. Read More>>
27Aug
Zylö’s ‘Powered by Z-pod®’ Technology Featured in XXIV’s New Product Line Launch
GREENVILLE, SC, UNITED STATES, August 20, 2025 /EINPresswire.com/ -- Zylö Therapeutics announced that its patented Z-pod® topical delivery platform has been incorporated into the initial launch of skincare brand XXIV’s new line, twentyfour. The debut includes two products formulated with Y100™-loaded Z-pods®: ⦁ StepZero™ — a topical powder designed for extended age-reversal ⦁ HYDRÍQ™ — a hydrator formulated for extended hydration and age-reversal "We are pleased to see our Z-pod® technology incorporated into XXIV’s product launch. Independent studies suggest this platform can extend...
27Aug
Archer Roose Wines Appoints California Beverage Solution as Statewide Distributor
NEW YORK, (Aug. 12, 2025) – Archer Roose Wines, the fast-growing canned wine brand, has named California Beverage Solution (CBS) as its statewide distributor partner. Under the new agreement, CBS will manage Archer Roose Wines’ distribution to restaurants, bars, grocery chains, convenience stores, and beverage retailers throughout California. Read More>>
21May
Gene and Cell Therapies in Focus at ASGCT 2025: Tackling Rare Diseases, Autoimmune Conditions, and More
Immusoft, a California-based cell therapy innovator, is presenting the world’s first clinical trial data for engineered B cells targeting mucopolysaccharidosis type I (MPS I), a rare genetic disorder caused by a deficiency in the enzyme iduronidase. This condition triggers a harmful buildup of substances, leading to severe developmental and physical challenges. At ASGCT 2025, Paul J. Orchard, MD, from the University of Minnesota, will share results from a first-in-human trial, highlighting the safety and early efficacy of autologous B cells...
21May